GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
A 16-year-old started using ketoconazole 2% and redensyl for hair loss, as minoxidil and finasteride are not recommended until age 18. They are seeking feedback on whether the treatment is effective or maintaining their hair.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.
The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.
Minoxidil sulfate is more effective than regular minoxidil, especially for those with low sulfotransferase levels or scalp sensitivity, but it is unstable unless delivered in a liposomal format. Combining minoxidil with tretinoin can enhance effectiveness, and stopping minoxidil use can lead to rapid hair loss.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
Micronutrient testing and deficiencies related to hair loss, particularly androgenetic alopecia (AGA). Discussion includes the impact of iron, selenium, zinc, copper, folate, B12, vitamin E, vitamin D, amino acids, and fatty acids, alongside treatments like dutasteride or finasteride.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.
A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
Men losing hair at a younger age, with theories including lifestyle factors like diet, pollution, and technology use. Treatments mentioned include Minoxidil and finasteride.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
A 46-year-old shared their successful hair regrowth journey using topical minoxidil, oral finasteride, ketoconazole shampoo, oral minoxidil, and head massages with lavender and peppermint oil, with noticeable improvement and no significant side effects except for darker eyelashes. They encourage others to try these treatments.
The conversation discusses the potential effects of soy isoflavones on hair loss, suggesting soy might counteract DHT due to its estrogenic properties. It also touches on the legitimacy of sources and anecdotal stories about soy consumption.
A dermatologist stated that minoxidil does not cause skin aging, despite online claims. A study found no significant impact of minoxidil on collagen content or skin aging.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.